Medtronic Lawsuit

Medtronic has recently recalled the following types of insulin pumps, which may put diabetic patients at risk of receiving too much or too little insulin and could have potentially fatal results:​

​

• MiniMed 600 Series Insulin Pumps

  • Model 630G (MMT-1715) - all lots before October 2019

  • Model 670G (MMT-1780) - all lots before August 2019

• Distribution Dates:

  • Model 630G - September 2016 to October 2019

  • Model 670G - June 2017 to August 2019

​​​

If you are interested in a free legal consultation to discuss your potential legal claim, contact our lawyers to learn more and determine if financial compensation may be available through a Medtronic recall settlement.

​

The ongoing litigation and recalls surrounding Medtronic insulin pumps continue to unfold, with new cases emerging as more patients report issues. Medtronic is likely to face continued legal and regulatory challenges as it works to address these concerns and improve the safety and reliability of its insulin pump products.

​

Patients using Medtronic insulin pumps are advised to stay informed about any recalls, updates, and safety information provided by the company and regulatory bodies, and to consult their healthcare providers if they have any concerns about their devices.

​

Key Issues with Medtronic Insulin Pumps

Medtronic has faced several lawsuits related to its insulin pumps, which are devices used by diabetes patients to deliver continuous insulin therapy. These lawsuits generally involve claims of device malfunctions, inadequate warnings, and severe health complications resulting from the use of the insulin pumps. Here’s an overview of the key issues and developments in these lawsuits:

​

Device Malfunctions:

• Software Glitches: Some lawsuits claim that software issues in the insulin pumps led to incorrect dosing of insulin, either too much or too little, which can cause severe health problems.

• Mechanical Failures: Allegations include problems with the device’s hardware, such as defective infusion sets, which could result in blockages or leaks, disrupting insulin delivery.

​

Inadequate Warnings and Instructions:

• Insufficient User Guidance: Plaintiffs have argued that Medtronic failed to provide adequate instructions or warnings about the potential risks and proper use of the insulin pumps.

• Failure to Recall: Some lawsuits claim that Medtronic did not promptly recall defective products or sufficiently notify users about known issues.

​

Health Complications:

• Hypoglycemia and Hyperglycemia: Incorrect insulin dosing can lead to dangerously low (hypoglycemia) or high (hyperglycemia) blood sugar levels, both of which can be life-threatening.

• Diabetic Ketoacidosis (DKA): A serious condition that can occur when the body doesn’t get enough insulin, leading to the buildup of ketones in the blood.

​

FDA Recalls:

• The U.S. Food and Drug Administration (FDA) has issued multiple recalls for various Medtronic insulin pump models. These recalls are usually classified based on the severity of the risk posed by the defect. For example, a Class I recall is the most serious, indicating that the device poses a significant risk of serious injury or death.